ALXO
HealthcareALX Oncology Holdings Inc.
$1.12
$-0.03 (-2.61%)
Jan 5, 2026
Price History (1Y)
Analysis
ALX Oncology Holdings Inc. is a biotechnology company operating in the healthcare sector. The company has a market capitalization of $60.72M and employs 44 individuals. Financially, ALX Oncology Holdings Inc. reported net income of -$108,010,000 and EBITDA of -$107,669,000 for the trailing twelve months. The company's cash position stands at $60.63M with debt totaling $15.61M. Returns on equity and assets are -118.9% and -50.5%, respectively, indicating significant losses. The debt to equity ratio is 34.84, while the current ratio is 2.40. The company's valuation metrics include a forward P/E of -1.49 and an EV/EBITDA of -0.16. The price to book ratio is 1.34, and the gross, operating, and profit margins are all at 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $60.72M
- P/E Ratio
- N/A
- 52-Week High
- $2.27
- 52-Week Low
- $0.40
- Avg Volume
- 314.28K
- Beta
- 0.52
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 44